Clinical bottom line
Refractory gastrointestinal (GI) motility disorders pose significant diagnostic and therapeutic challenges. Recent advances in diagnostic modalities, including high-resolution manometry and novel endoscopic techniques such as third space endoscopy, have enhanced evaluation and treatment options. Emerging therapies targeting underlying pathophysiology, including pharmacologic agents and minimally invasive endoscopic interventions, show promise in improving symptoms and quality of life. However, heterogeneity in patient populations and limited large-scale trials necessitate individualized, multidisciplinary approaches (Carrington et al., 2018; Nabi et al., 2021).
What the evidence shows
Accurate diagnosis of refractory GI motility disorders relies on advanced functional testing. Carrington et al. (2018) provide expert consensus on anorectal function evaluation, emphasizing high-resolution anorectal manometry and balloon expulsion tests to delineate defecatory disorders.
Nabi et al. (2021) highlight the expanding role of third space endoscopy, including peroral endoscopic myotomy (POEM), as a minimally invasive treatment for esophageal motility disorders such as achalasia, with favorable short- and mid-term outcomes.
Pharmacologic advances include potassium-competitive acid blockers and novel prokinetic agents, which may benefit subsets of patients with refractory symptoms, as reviewed by Hossa et al. (2025) and Cable et al. (2026).
Endoscopic management strategies are evolving, with recent reviews underscoring their utility in selected patients with refractory symptoms unresponsive to medical therapy (Perspectives in Surgery, 2022).
Pediatric and adolescent populations present unique challenges; Lu et al. (2023) discuss tailored diagnostic and therapeutic approaches in this group.
Gwee et al. (2016) provide a framework for approaching refractory constipation, integrating motility testing and biofeedback therapy.
Caveats and uncertainty
Heterogeneity in motility disorder phenotypes complicates standardization of diagnostic criteria and treatment algorithms.
Long-term efficacy and safety data for novel endoscopic and pharmacologic therapies remain limited.
Access to specialized diagnostic tools and expertise may be restricted in some settings.
Placebo effects and symptom variability require cautious interpretation of therapeutic outcomes.
Multidisciplinary collaboration is essential but may be logistically challenging.
How this may change practice
Incorporation of advanced motility testing can refine diagnosis and guide targeted therapy.
Third space endoscopy techniques like POEM may become first-line interventions for select esophageal motility disorders refractory to medical management.
Emerging pharmacotherapies offer additional options for symptom control, particularly in gastroesophageal reflux disease and gastroparesis overlap syndromes.
Personalized treatment plans integrating medical, endoscopic, and behavioral therapies can optimize outcomes.
Increased awareness and training in motility disorders among gastroenterologists will improve patient care.
Ongoing research and clinical trials will further define best practices and expand therapeutic armamentarium.